siRNA treatment reduces triglycerides in individuals with rare disorder

.RESEARCH STUDY HIGHLIGHT.19 September 2024.

Plozasiran reduced triglyceride amounts by 80% and also lowered the risk of pancreatitis in clients with persistent chylomicronemia, with or without a genetic medical diagnosis.